Medtronic Buys Bladder-Control Neurostimulation Firm
This article was originally published in The Gray Sheet
Medtronic plans to launch Advanced Uro-Solutions’ 510(k)-cleared Nuro percutaneous tibial nerve stimulation system in the next year following its Feb. 23 acquisition of the firm.
You may also be interested in...
Neuromodulation for urological indications, notably overactive bladder (OAB), has been dominated since the late 1990s by Medtronic’s sacral-nerve stimulation system InterStim, with the more recent addition of Cogentix Medical’s Urgent PC for tibial nerve stimulation. Yet only a fraction of OAB patients receive effective neuromodulation treatment, and several companies hope to lower barriers to this modality by developing alternative devices for urological indications.
The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.
The firm is expanding its leadership position in the urology space with its acquisition of American Medical Systems's men's health and prostate health units.